Association Between Vaccination With BNT162b2 and Incidence of Symptomatic and Asymptomatic SARS-CoV-2 Infections Among Health Care Workers

Editorial Material Medicine, General & Internal

SARS-CoV-2 Viral Variants-Tackling a Moving Target

John R. Mascola et al.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Letter Medicine, General & Internal

Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients

Sharon Amit et al.

LANCET (2021)

Add to Collection

Article Medicine, General & Internal

BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting

Noa Dagan et al.

Summary: A study conducted in Israel on nearly 600,000 individuals showed that the BNT162b2 mRNA vaccine was effective in reducing the risk of infection, hospitalization, and severe Covid-19. The effectiveness in preventing death was 72% during the period from day 14 through day 20 after the first dose, and hospitalization was reduced by 87% for the period 7 or more days after the second dose, similar to results from a randomized trial.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Health Policy & Services

Israel's rapid rollout of vaccinations for COVID-19

Bruce Rosen et al.

Summary: Israel has stood out for its rapid and effective COVID-19 vaccine rollout, with factors contributing to its success falling into categories of long-standing characteristics, health-system specific features, and recent efforts specific to the vaccination campaign. The synergy created among these facilitating factors has been crucial in Israel's success, distinguishing it from other high-income countries like the US, the UK, and Canada that have faced slower vaccine distribution due to lacking some of these factors.

ISRAEL JOURNAL OF HEALTH POLICY RESEARCH (2021)

Add to Collection

Article Public, Environmental & Occupational Health